Fertility doc backs off on custom kids
By United Press International,
United Press International
| 03. 04. 2009
A New York fertility doctor says he will be limiting his genetics work to dodging diseases rather than customizing physical traits such as hair and eye color.
Dr. Jeff Steinberg caused a stir this week with claims that he could help parents predetermine various characteristics of future offspring but the New York Daily News said Wednesday he is holding off for the time being.
"We are going to limit it to people with genetic diseases because we just cannot keep up with what's going on," Steinberg said.
Steinberg's clinics in New York and Los Angeles will be focusing on such disorders as color blindness and albinism, the newspaper said.
The Daily News said word of Steinberg's ability to select embryos with desirable physical traits and gender appalled some New York parents while others thought it was a great idea.
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...